ATx201

Phase I study – 36 Healthy volunteers:

  • Study ID: ATx201-001 (DECOLAD, Part 1)
  • Place: Austria
  • Randomized, double-blind, placebo controlled study
  • 36 healthy volunteers
  • Split body design
  • 7-day treatment, maximal dose
  • Safety of formulation (Systemic exposure: Blood PK, biomarkers and irritation)

For more information about this study please visit clinicaltrialsregister.eu and clinicaltrials.gov

 

Phase I Study - Irritation Potential (30 Healthy Volunteers)

  • Study ID: ATx201-006
  • Place: US
  • Randomized, double-blind, placebo controlled study
  • 30 healthy volunteers, intact and abraded skin
  • Safety
  • 21-days treatment
  • Multiple doses

For more information about this study please visit clinicaltrialsregister.gov

 

Phase I Study - Sensitization Potential (200 Healthy Volunteers)

  • Study ID: ATx201-005
  • Place: US
  • Randomized, double-blind, placebo controlled study
  • 200 healthy volunteers
  • Safety
  • Minimum 41-days participation period
  • Multiple doses

For more information about this study please visit clinicaltrialsregister.gov

 

Learn more